EXELIXIS, INC.
EXEL · XNASCIK 939767fmd_13RX4VPZZ7D1SMJAENA3RQ1NHVManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Oct 02, 2026, 86 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 191 | 452 | 854 | 968 | 988 | 1,435 | 1,611 | 1,830 | 2,169 | 2,320 |
| Cost of revenue | 7 | 15 | 26 | 33 | 36 | 53 | 58 | 73 | 76 | 84 |
| Gross profit | 185 | 437 | 827 | 935 | 951 | 1,382 | 1,553 | 1,758 | 2,092 | 2,236 |
| Research and development | 96 | 112 | 182 | 337 | 548 | 694 | 892 | 1,044 | 910 | 825 |
| Selling, general and administrative | 116 | 159 | 206 | 228 | 293 | 402 | 460 | 543 | 492 | 519 |
| Total operating expenses | 220 | 287 | 415 | 598 | – | – | – | – | – | – |
| Operating income | (28) | 166 | 439 | 369 | 110 | 287 | 201 | 171 | 605 | 872 |
| Interest expense | 33 | 9 | 0 | 0 | – | – | – | – | – | – |
| Other non-operating income (expense) | (42) | (7) | 13 | 29 | 1 | (0) | (0) | 0 | (0) | (0) |
| Income before taxes | (70) | 159 | 452 | 398 | 131 | – | – | – | – | – |
| Income tax expense | 0 | 4 | (238) | 77 | 19 | 63 | 52 | 50 | 160 | 159 |
| Net income from continuing operations | (70) | 154 | 690 | 321 | 112 | – | – | – | – | – |
| Net income | (70) | 154 | 690 | 321 | 112 | 231 | 182 | 208 | 521 | 783 |
| Net income to common shareholders | (70) | 154 | 690 | 321 | – | – | – | – | – | – |